arrow
C

Cristina Viaplana

vall dhebron barcelona hospital campus
H指数:14
被引数:1,166

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Quality and safety of research biopsies in oncology clinical trials.

肿瘤临床试验中研究活检的质量与安全。

2026-05-250
OAAI
Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors

基因组可操作性及匹配的靶向疗法在为期十年的机构实体瘤精准医学项目中的应用

2025-11-060
OAAI
A CT-based deep learning-driven tool for automatic liver tumor detection and delineation in patients with cancer

一种基于CT的、由深度学习驱动的自动肝脏肿瘤检测与勾画工具,用于癌症患者

2025-04-010
OAAI
Development of a prognostic model to predict 90-day mortality in hospitalised cancer patients (PROMISE tool): a prospective observational study

预测住院癌症患者90天死亡率的预后模型的开发 (PROMISE工具): 一项前瞻性观察研究

2024-11-010
OA
Impact of treatment beyond progression (TBP) in patients treated with immunotherapy (IO) in phase I trials (Ph1)

免疫治疗(IO)在I期临床试验(Ph1)中,治疗超越进展(TBP)的影响

2024-09-010
PRE
the TEOGIC study project: a comprehensive characterization of early onset gastrointestinal cancer in the Northern area of Spain (vol 24, pg 668, 2024)
2024-07-090
OAAI
The TEOGIC study project: a comprehensive characterization of early onset gastrointestinal cancer in the Northern area of Spain
2024-06-011
OAAI
LOXL2-mediated chromatin compaction is required to maintain the oncogenic properties of triple-negative breast cancer cells
2024-03-071
PRE
Quality and safety of research biopsies (RB) in oncology clinical trials

肿瘤学临床试验中研究活检 (RB) 的质量和安全性

2023-10-010
OA
Early-Stage Breast Cancer Detection in Breast Milk
2023-09-1411
OAAI
ctDNA IN BREAST MILK FOR EARLY DETECTION OF PREGNANCY ASSOCIATED BREAST CANCER
2023-03-010
PRE
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer (September, 10.1038/s41467-022-32828-6, 2022)

高p16表达和杂合RB1丢失是ER乳腺癌中CDK4/6抑制剂抗性的生物标志物 (9月,10.1038/s41467-022-32828-6,2022)

2022-11-140
OAAI
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer

高p16表达和杂合RB1缺失是ER乳腺癌中CDK4/6抑制剂耐药的生物标志物

2022-09-0747
OAAI
Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification

用于鉴定同源重组缺陷肿瘤和患者分层的RAD51测试的临床前体内验证

2022-02-1645
OA
High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer
2022-01-0515
OA
OncoTree: A Cancer Classification System for Precision Oncology
2021-12-0167
OA
Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials
2021-09-011
OA